Ku0063794

Manufactured by Cayman Chemical

Sourced in United States

KU0063794 is a laboratory item designed for use in scientific research and analysis. It serves as a tool for conducting various experiments and procedures within a controlled laboratory environment. The core function of this product is to facilitate data collection and analysis, without further interpretation of its intended use.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using ku0063794

Evaluation of Combination Targeted Therapies

Check if the same lab product or an alternative is used in the 5 most similar protocols

NVP-AEW541 and NVP-BEZ235 were gifts from Novartis (Basel, Switzerland). Lapatinib, KU0063794 and LY294002 were from Cayman Chemical (Michigan, USA). Cisplatin was purchased from Sigma-Aldrich (Steinheim, Germany). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased from Serva (Heidelberg, Germany). Propidium iodide was from PromoCell (Heidelberg, Germany). Roswell Park Memorial Institute (RPMI) media 1640, Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin/streptomycin [10,000 U/ml; 10 mg/ml] and trypsin-EDTA (0.05% trypsin, 0.02% EDTA in PBS) were purchased from PAN Biotech (Aidenbach, Germany). Primary antibodies were purchased from R&D Systems (Wiesbaden, Germany) (p IGF1R, IGF1R, p-EGFR, EGFR, p-ErbB2, ErbB2, p-ErbB3, ErbB3) or Santa Cruz Biotechnology (Heidelberg, Germany) (p-Akt, Akt, β-Actin, PARP). HRP-conjugated secondary antibodies were from R&D Systems. All other reagents and chemicals were from VWR BDH PROLABO (Darmstadt, Germany).

Gohr K., Hamacher A., Engelke L.H, & Kassack M.U. (2017). Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38. BMC Cancer, 17, 711.

+ Open protocol

+ Expand

Pharmacological Inhibitors and Peptide Regulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

Rapamycin, Torin 1, Torin 2, Temsirolimus, XL765, Ku-0063794, FK-506, and NF-449 were purchased from Cayman Chemical (Ann Arbor MI) and prepared in DMSO at 25 mg/mL. Trehalose was obtained from Sigma Aldrich (St. Louis MO), and prepared in DMSO at 250 mg/mL. Tat-Beclin 1(tat-Bec1) human recombinant peptide was purchased from EMD Millipore (Billerica MA) and prepared at concentrations of 25 and 125 mg/mL. Cell culture grade dimethyl sulfoxide (DMSO) was obtained from Thermo Fisher (Waltham MA).

Vogel K.R., Ainslie G.R, & Gibson K.M. (2016). mTOR Inhibitors Rescue Premature Lethality and Attenuate Dysregulation of GABAergic/Glutamatergic Transcription in Murine Succinate Semialdehyde Dehydrogenase Deficiency (SSADHD), a Disorder of GABA Metabolism. Journal of inherited metabolic disease, 39(6), 877-886.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!